摘要
我国丙型病毒性肝炎(丙肝)患者总数位居全球首位,直接抗病毒药物(DAA)的出现颠覆了丙肝领域的治疗模式,使消除丙肝公共卫生威胁成为可能。近年来,DAA开始陆续进入了我国部分地区的省级医保目录,随后通过药品谈判进入国家医保目录,各统筹地区实行不同的门诊报销政策。本文通过查阅文献、政府官网和其他相关资料,对我国丙肝的流行情况、国内外丙肝防控策略、我国丙肝治疗药物医疗保障政策等进行综述,为提高我国丙肝治疗的可及性和可负担性提供参考依据。
The number of hepatitis C patients in China ranks first in the world.Direct-acting antiviral agents(DAAs)have overturned the treatment model for hepatitis C,making it possible to eliminate hepatitis C.In recent years,DAA have entered the provincial health insurance drug list in some regions of China firstly,and then were included in national reimbursement drug list by price negotiation with different outpatient reimbursement policies.By reviewing literature,government websites and other related materials,the prevalence of hepatitis C,domestic and foreign hepatitis C prevention and control strategies,health insurance policies for hepatitis C and related issues were summarized,so as to provide implications for improving the accessibility and affordability of hepatitis C treatment.
作者
魏霞
杨莉
WEI Xia;YANG Li(Health Policy and Technology Assessment Center,School of Public Health,Peking University Health Science Center,Beijing 100191,China)
出处
《临床药物治疗杂志》
2021年第12期1-5,共5页
Clinical Medication Journal
基金
国家自然科学基金(72174010、71673004、71911530221)
。
关键词
直接抗病毒药物
丙型病毒性肝炎
医疗保障
谈判
direct-acting antiviral agent
hepatitis C
health insurance
national negotiation
